INDV
Overvalued by 192.2% based on the discounted cash flow analysis.
Market cap | $2.89 Billion |
---|---|
Enterprise Value | $2.99 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $0.01 |
Beta | 0.2 |
Outstanding Shares | 134,848,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -10.31 |
---|---|
PEG | 10 |
Price to Sales | 1.1 |
Price to Book Ratio | -2.94 |
Enterprise Value to Revenue | 2.52 |
Enterprise Value to EBIT | 16.42 |
Enterprise Value to Net Income | -1350 |
Total Debt to Enterprise | 0.14 |
Debt to Equity | -1.21 |
No data
No data
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...